Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963090 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance Foundation Trials.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02963090: Clinical Trial Phase 2 study, sponsored by Alliance Foundation Trials.
NCT02963090 is a Phase 2 study that was terminated before completion, run by Alliance Foundation Trials. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963090, a Phase 2 study, was terminated before completion, sponsored by Alliance Foundation Trials.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a multi-institutional, randomized, open-label phase II study of pembrolizumab compared to topotecan, administered to patients with SCLC who have progressed or relapsed after first-line treatment with etoposide and platinum. Patients will be randomized in a 2:1 fashion to receive pembrolizumab or topotecan. Participants in the topotecan arm that progress will be allowed to cross-over to the pembrolizumab arm.
Primary Outcome
This phase II study will determine if there is a benefit in progression free survival (PFS) for SCLC patients receiving pembrolizumab (Experimental arm) as compared to topotecan (Control arm) in the second-line settingSCLC patients receiving pembrolizumab (Experimental arm) as compared to topotecan (Control arm) in the second-line setting. RECIST Version 1.1 was used in this study for assessment for tumor response. Progression (PD): At least one of the following must be true: a. At least one new
Interventions
- DRUG Pembrolizumab
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-05-20 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 2 |
Why NCT02963090 stopped before completion
NCT02963090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02963090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02963090 about?
NCT02963090 is a clinical study titled "Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer". This is a multi-institutional, randomized, open-label phase II study of pembrolizumab compared to topotecan, administered to patients with SCLC who have progressed or relapsed after first-line treatment with etoposide and platinum. Patients will be randomized in a 2:1 fashion to receive pembrolizuma...
What is the current status of trial NCT02963090?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-05-20. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02963090?
The interventions under investigation include: Pembrolizumab (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT02963090?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02963090's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI